2012-12-28Zeitschriftenartikel DOI: 10.1007/s10198-012-0452-1
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
After acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)—a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85 % of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004–2009. Identification of HZ- and PHN-cases was performed based on ‘International Statistical Classification of Diseases’ and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5 % of HZ-cases developed PHN. One HZ-case caused on average €210 and €376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of €1,123 (€1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at €182 million (€105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.
Dateien zu dieser Publikation
Anzeige der Publikationen mit ähnlichem Titel, Autor, Urheber und Thema.
2011-06-16ZeitschriftenartikelHerpes zoster in Germany: Quantifying the burden of disease Ultsch, Bernhard; Siedler, Anette; Rieck, Thorsten; Reinhold, Thomas; Krause, Gérard; Wichmann, OleBackground: Herpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects individuals aged ≥ 50 years. Vaccines have been licensed or are under development that can protect against ...
2015-06-05ZeitschriftenartikelSystematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries Damm, Oliver; Ultsch, Bernhard; Horn, Johannes; Mikolajczyk, Rafael T.; Greiner, Wolfgang; Wichmann, OleBackground: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. Methods: A PubMed search ...
2011-09-09ZeitschriftenartikelCalculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort. Stoll, Matthias; Kollan, Christian; Bergmann, Frank; Bogner, Johannes; Faetkenheuer, Gerd; Fritzsche, Carlos; Hoeper, Kirsten; Horst, Heinz-August; Lunzen, Jan van; Plettenberg, Andreas; Reuter, Stefan; Rockstroh, Jürgen; Stellbrink, Hans-Jürgen; Hamouda, Osamah; Bartmeyer, BarbaraBackground/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide ...